11. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate‐to‐severe plaque psoriasis. (December 2013) Authors: Zhu, B.; Edson‐Heredia, E.; Cameron, G.S.; Shen, W.; Erickson, J.; Shrom, D.; Wang, P.; Banerjee, S.; Gordon, K.B. Journal: British journal of dermatology Issue: Volume 169:Number 6(2013:Dec.) Page Start: 1337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. (14th December 2017) Authors: Gordon, K.B.; Blauvelt, A.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Shen, Y.K.; You, Y.; Griffiths, C.E.M. Journal: British journal of dermatology Issue: Volume 178:Number 1(2018) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. (1st January 2018) Authors: Gordon, K.B.; Blauvelt, A.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Shen, Y.K.; You, Y.; Griffiths, C.E.M. Journal: British journal of dermatology Issue: Volume 178:Number 1(2018) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Impact of brodalumab treatment on psoriasis symptoms and health‐related quality of life: use of a novel patient‐reported outcome measure, the Psoriasis Symptom Inventory. (1st March 2014) Authors: Gordon, K.B.; Kimball, A.B.; Chau, D.; Viswanathan, H.N.; Li, J.; Revicki, D.A.; Kricorian, G.; Ortmeier, B.G. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Impact of brodalumab treatment on psoriasis symptoms and health‐related quality of life: use of a novel patient‐reported outcome measure, the Psoriasis Symptom Inventory. (March 2014) Authors: Gordon, K.B.; Kimball, A.B.; Chau, D.; Viswanathan, H.N.; Li, J.; Revicki, D.A.; Kricorian, G.; Ortmeier, B.G. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3. (1st August 2018) Authors: Papp, K.A.; Gordon, K.B.; Langley, R.G.; Lebwohl, M.G.; Gottlieb, A.B.; Rastogi, S.; Pillai, R.; Israel, R.J. Journal: British journal of dermatology Issue: Volume 179:Number 2(2018) Page Start: 320 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3. (23rd May 2018) Authors: Papp, K.A.; Gordon, K.B.; Langley, R.G.; Lebwohl, M.G.; Gottlieb, A.B.; Rastogi, S.; Pillai, R.; Israel, R.J. Journal: British journal of dermatology Issue: Volume 179:Number 2(2018) Page Start: 320 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study. (7th November 2019) Authors: Lebwohl, M.G.; Gordon, K.B.; Gallo, G.; Zhang, L.; Paul, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 2(2020) Page Start: 301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2). (1st April 2021) Authors: Gordon, K.B.; Warren, R.B.; Gottlieb, A.B.; Blauvelt, A.; Thaçi, D.; Leonardi, C.; Poulin, Y.; Boehnlein, M.; Brock, F.; Ecoffet, C.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 4(2021) Page Start: 652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2). (9th September 2020) Authors: Gordon, K.B.; Warren, R.B.; Gottlieb, A.B.; Blauvelt, A.; Thaçi, D.; Leonardi, C.; Poulin, Y.; Boehnlein, M.; Brock, F.; Ecoffet, C.; Reich, K. Journal: British journal of dermatology Issue: Volume 184:Number 4(2021) Page Start: 652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗